A Phase 1 clinical trial evaluating single ascending doses and multiple ascending doses of ATI-052
Latest Information Update: 27 Jun 2025
At a glance
- Drugs BSI 502 (Primary)
- Indications Autoimmune disorders; Respiration disorders; Skin disorders
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 23 Jun 2025 According to an Aclaris Therapeutics media release, Company expects to complete the Phase 1a SAD/MAD portion by year-end 2025 and provide top line results in early 2026, followed by the top line results from the Phase 1b portion in the second half of 2026.
- 23 Jun 2025 Status changed from planning to not yet recruiting as per the Aclaris Therapeutics media release .
- 22 Apr 2025 According to Aclaris Therapeutics media release, Company expects to initiate the trial in the second quarter of 2025.